Seasoned Health Care Executives Supplement Veridien Management Team; to Assist in Driving Planned Growth.

ST. PETERSBURG, Fla. -- Veridien Corporation (OTCBB:VRDE) recently announced its equity investment in and right to acquire a majority interest in Mycosol, Inc. a development-stage chemical and pharmaceutical development company, located in Research Triangle Park area of North Carolina. As part of the agreement, key members of the Mycosol management team have agreed to focus on assisting Veridien expansion in the areas of marketing, sales, research and technology development.

Mycosol's senior executives have already begun working with Veridien to provide operational, technical, and product development support to expand the current Viraguard anti-infectives product portfolio and increase market penetration

Sheldon C. Fenton, President and C.E.O. of Veridien Corporation stated: "Quality companies are built on quality management. We are pleased to welcome these 3 talented executives to our team and look forward to their contributions to our future successes."

Mycosol's key management includes Richard B. Klein (recently appointed to Veridien's Board of Directors), Jeffrey Selph and James Hriso.

Mr. Klein, a Co-Founder of Mycosol Inc., serves as Mycosol's Chairman and Chief Executive Officer. He is a 30-year veteran of the healthcare industry, having served in a general management capacity at both large and small (early-stage) companies, including: ArgoMed, Angiosonics, Edward Weck Company (subsidiary of Bristol-Myers Squibb), and Bard Medsystems Division (of C.R. Bard). During his career, Mr. Klein has led some significant product development efforts and market introductions, including: balloon angioplasty, patient controlled analgesia (PCA), the Mini-Infuser and "Smart" Pump drug delivery systems, minimally invasive surgery (laparoscopy), endometrial and prostatic ablation by thermotherapy, and ultrasound thrombus ablation. He holds both a BS and an MS in Engineering from Northeastern University, an MBA from Babson College, and was the subject of a Harvard Case Study on intrapreneurs - i.e., entrepreneurs who work in large companies - which was featured in a 1988 business text, General Managers In Action, by Francis Joseph Agular. He also holds numerous medical device patents, issued or pending.

Mr. Selph, a Co-Founder Mycosol Inc., serves as Mycosol's President and Chief Operating Officer. He has 30+ years experience in the pharmaceutical industry with Burroughs Wellcome, GlaxoWellcome, and GlaxoSmithKline. More recently Mr. Selph was Co-Founder of Trelion Pharmaceuticals, Cytospect Pharma, and Avera Pharmaceuticals. During his career, Mr. Selph served as Development Project Leader for different development compounds in the areas of pain, anti-inflammation, immunosuppression, and oncology. Mr. Selph was the Pre-clinical Research Representative to two International Product Development Teams for pain and leukemia. He was responsible for - and led - the RTP Inflammation and Pain Sections in vivo efforts and, in addition, headed Burroughs Wellcome's Inflammation and Analgesia Labs and Analgesic Study Group. Mr. Selph has authored or co-authored more than 50 peer-review publications and seven patents (3 issued and 4 pending). Mr. Selph holds a BS degree from East Carolina University.

Mr. Hriso serves as Mycosol Inc.'s Vice President of Business Development with a focus on strategic market analysis and planning for the Company. He has over 30 years of pharmaceutical industry experience - primarily, with the Burroughs Wellcome (BW) Company - where he was involved in the development, introduction, marketing, and promotion of anti-bacterial, respiratory, CNS, cardiac, pain, and anti-viral drugs as well as numerous OTC products. Mr. Hriso held several management positions at BW, including: responsibility for marketing and sales throughout the Pacific Basin, Brand Manager for urologic anti-bacterial medicines and a new OTC anti-inflammatory medicine for the U.S. market, West Coast Sales Manager for a broad portfolio of hospital products, and Account Manager for all HMO, PBO, Nursing Home, and State Medicaid business in the newly formed Managed Care Division. Mr. Hriso has a BA from Allegheny College, an ABA from Gaston College, and an MBA from Chaminade University.

About Veridien:

Veridien Corporation is a Health Care and Anti-Infectives Company focusing on Infection Control and other Healthy Lifestyle products. Veridien has developed patented and unique products including surface disinfectants, antiseptic hand cleansers, instrument presoak, and sun protectant products. The flagship product, Viraguard(R) Hospital Disinfectant/Cleaner and Instrument Presoak is a skin friendly, patented, U.S. - EPA and Health Canada registered, surface disinfectant. Viraguard(R) Antiseptic Hand Gel, Viraguard(R) Antiseptic Hand Spray and Viraguard(R) Antiseptic Hand Wipes are U.S. - FDA and Health Canada drug listed products utilizing Veridien's patented Virahol(R) formulation.

Look for Veridien at http://www.veridien.com

About Mycosol / Veridien's investment in future technology:

Mycosol is a development-stage chemical and pharmaceutical company based in the Research Triangle Park area of North Carolina. The Company is developing a proprietary, low cost platform technology with the objective being to safely and effectively treat and prevent microbial-induced and microbial-exacerbated problems. Mycosol's proprietary multi-active compound has demonstrated potent anti-fungal, anti-bacterial, anti-inflammatory, and anti-allergic properties. Using this 'core technology' platform, a library of over 1,500 known analogs and 5 patents pending, Mycosol believes that a broad portfolio of products can be developed for many medical, industrial, veterinary and agricultural applications.

Look for Mycosol at http://www.mycosol.com

Special Note: Forward-looking statements in this press release are made pursuant to the "safe-harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statement involve risks and uncertainties, including without limitation, market acceptance of, and demand for, the Company's products, manufacturing, development and distributor issues, product pricing, competition, funding availability, technological changes and other risks not identified herein. The Company disclaims any intent or obligation to update any forward-looking statements.

"Healthy Living is an Adventure - Let Veridien Guide You"